<SEC-DOCUMENT>0001144204-17-010513.txt : 20170223
<SEC-HEADER>0001144204-17-010513.hdr.sgml : 20170223
<ACCEPTANCE-DATETIME>20170223092455
ACCESSION NUMBER:		0001144204-17-010513
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170223
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170223

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		17630984

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v460201_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 3pt; border-top: Black 1.5pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported):
<B>February 23, 2017</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3333 Lee Parkway, Suite 600</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Dallas, TX 75219</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>(214)-665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01.&nbsp;&nbsp;Other Events </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 23, 2017, Abeona Therapeutics
Inc. issued a press release entitled &ldquo;Abeona Therapeutics Announces Voluntary Dismissal of Securities Class Action Lawsuit&rdquo;.
The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Financial Statements
and Exhibits. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; padding: 0; text-decoration: underline; text-indent: 0"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 90%; padding: 0; text-decoration: underline; text-indent: 0"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-size: 10pt">Press release dated February 23, 2017, entitled &ldquo;Abeona Therapeutics Announces Voluntary Dismissal of Securities Class Action Lawsuit&rdquo; </FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Abeona Therapeutics Inc.</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 51%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 46%; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>/s/ Stephen B. Thompson</U></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT><BR>
<FONT STYLE="font-size: 10pt">Vice&nbsp;President&nbsp;Finance </FONT><BR>
<FONT STYLE="font-size: 10pt">Chief&nbsp;Accounting Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: February 23, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 1pt; margin-bottom: 1pt"></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Exhibit Number </U></FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">Press release dated February 23, 2017, entitled &ldquo;Abeona Therapeutics Announces Voluntary Dismissal of Securities Class Action Lawsuit&rdquo; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v460201_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>EX 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;<IMG SRC="image_logo.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Announces Dismissal
of Securities Class Action Lawsuit</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Securities Class Action Lawsuit
lacked any valid basis and was voluntarily dismissed </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>New York, NY, and Cleveland, OH</B>
&ndash; <B>February 23, 2017 - </B>Abeona Therapeutics Inc. (Nasdaq: ABEO), <FONT STYLE="background-color: white">a leading clinical-stage
biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases</FONT>, announced today that
on February 14, 2017, the plaintiff voluntarily dismissed the putative securities class action lawsuit he had recently filed against
the company and certain members of its management, following the Company&rsquo;s demand that the case be dismissed because it lacked
a valid legal and factual basis. The plaintiff based his Complaint, in its entirety, on allegations that been cut and pasted from
an internet blog article. No payment or any other consideration was paid by, or on behalf of, the Company or its management in
connection with the lawsuit&rsquo;s dismissal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are gratified to have brought
about the prompt dismissal of this meritless case just two months after it began, as it should never have been filed at all,&rdquo;
said Jordan D. Hershman of Morgan, Lewis &amp; Bockius LLP, lead counsel for the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>About
Abeona: </I></B><FONT STYLE="color: #26282A">Abeona Therapeutics Inc. is a leading clinical-stage biopharmaceutical company developing
gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH) and ABO-101 (AAV-NAGLU),
adeno-associated virus (AAV) based genetic therapies for Sanfilippo syndrome (MPS IIIA and IIIB, respectively). Abeona is also
developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis
bullosa (EB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) gene therapy for treatment
of infantile Batten disease (INCL), and ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based
gene editing approach to gene therapy for rare blood diseases. In addition, Abeona has a plasma-based protein therapy pipeline,
including SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited COPD, using its proprietary SDF&trade; (Salt Diafiltration)
ethanol-free process. For more information, visit&nbsp;</FONT></FONT><FONT STYLE="color: #0081F2"><U>www.abeonatherapeutics.com</U></FONT><FONT STYLE="color: #26282A; background-color: white">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #26282A"><I>This press release contains
certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements are subject to numerous risks and uncertainties, including but not limited to
continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition;
the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact
of changes in the financial markets and global economic conditions; our belief that initial signals of biopotency and clinical
activity, which suggest that ABO-102 successfully reached target tissues throughout the body, including the central nervous system;
our belief that the data demonstrate an early and robust systemic delivery of ABO-102, and the increased reductions in CNS GAG
support our approach for intravenous delivery for subjects with Sanfilippo syndromes, and other risks as may be detailed from time
to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission.
The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update
them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future
developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white"><B><I>Investor
Contact:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Christine Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Abeona Therapeutics Inc.<BR>
+1 (212)-786-6212</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">csilverstein@abeonatherapeutics.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Contact:</B><BR>
Andre&rsquo;a Lucca<BR>
Vice President, Communications &amp; Operations<BR>
Abeona Therapeutics Inc.<BR>
+1 (212)-786-6208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">alucca@abeonatherapeutics.com</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !W 2H# 2(  A$! Q$!_\0
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M'^%8EK=W/PR\3:LE[IUS/H6HS&XAN+9-_E'DX(_''X UO1_%OP@ZY:]GC/\
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M0E%+5&0F@O;J8[35+VWAR2(E*,%R<X&5) JYI^G1:='(J222O*_F22RMEG;
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MLLJN,,H..>1113<FQ)) 0&&" 1Z&EP,Y[T44AB;1C&!CTH"J%VA0%] .***
M%I" PP0"/0T44 #*KC#*&'H1FEHHH ,#.>])@>@HHH 7 SFD"JO10,G/ HHH
M 6D554850/H*** %I%54&%4 >@&***  *H.0H&3G@4H '2BB@!-B[MVT;O7'
..-+@9SCFBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
